Keyphrases
Mucin 1 (MUC1)
100%
Triple-negative Breast Cancer
100%
Adoptive Cell Therapy
100%
Tumor-specific
100%
Triple-negative Breast Cancer Cells
33%
T Cells
20%
Targeted Therapy
13%
Human Triple Negative Breast Cancer
13%
Engineered T Cells
13%
Treatment Refractory
13%
Tumor
13%
Her2neu
6%
Solid Tumors
6%
Mouse Model
6%
Healthy Cells
6%
Tumor Explant
6%
Progesterone
6%
National Cancer Institute
6%
Clinical Trials
6%
Life-threatening
6%
Antibody Fragment
6%
Immune Cells
6%
Clinical Collaboration
6%
Toxicity Issues
6%
Optimal Target
6%
Toxic Environment
6%
Cancer Antigen
6%
Blood Cancer
6%
Tumor Cells
6%
Immune System
6%
Human Disease
6%
Recurrence Rate
6%
Survival Rate
6%
Chemorefractory Disease
6%
Estrogen
6%
Metastatic Triple-negative Breast Cancer
6%
TAB004
6%
Immune Therapy
6%
Disease Progression
6%
High Risk
6%
Breast Tumor
6%
Epithelial Cells
6%
Scientific Expertise
6%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
100%
Mucin 1
100%
Triple Negative Breast Cancer
100%
Malignant Neoplasm
13%
Disease
13%
Immunotherapy
13%
Side Effect
6%
Clinical Trial
6%
Progesterone
6%
Solid Malignant Neoplasm
6%
Disease Exacerbation
6%
Tumor Antigen
6%
Survival Rate
6%
Infection
6%
Mouse Model
6%
Recurrent Disease
6%
Immunology and Microbiology
MUC1
100%
Cancer Cell
33%
T Cell
26%
Monospecific Antibody
13%
Immunotherapy
13%
Tumor Cell
6%
Tumor Antigen
6%
Survival Rate
6%
Immunocompetent Cell
6%
Chimeric Antigen Receptor T-Cell
6%
Explant
6%
Immune System
6%
Mouse Model
6%